Pirfenidone is used to treat idiopathic pulmonary fibrosis (IPF),1 a progressive disease that causes irreversible lung scarring and makes it difficult to breathe2Approximately 140,000 Americans live with IPF, a rare disease with no cure, and 50,000 new…
Entries by https://www.sandoz.com/rss/feeds/news/media-releases.xml
Ad hoc announcement pursuant to Art. 53 LRQ1 sales grew +5% (cc1, +1% USD), core operating income grew +9% (cc, +3% USD)Innovative Medicines (IM) sales grew +4% (cc, +1% USD) and core operating income +5% (cc, 0% USD)Strong performance of key growth br…
Brimonidine tartrate/timolol maleate combination eyedrop is used to treat elevated eye pressure in patients with ocular hypertension1Ocular hypertension affects over 5% of all adults2; the eye does not properly drain fluid, causing eye pressure to buil…
Extending existing master services agreement with Ares Genetics, to develop digital platform for development and life cycle management of antibiotics, to January 31, 2025 Both parties strengthening focus on antibiotic stewardship and planning to engage…
Extending existing master services agreement with Ares Genetics, to develop digital platform for development and life cycle management of antibiotics, to January 31, 2025 Both parties strengthening focus on antibiotic stewardship and planning to engage…
Sandoz gains significant capabilities and assets in medical and drug device development that target major growth opportunities in respiratory and complex genericsRespiratory diseases are leading cause of death and disability and impose huge financial b…
Lenalidomide Sandoz is indicated for use in several critical haematology-oncology conditions, per latest ESMO guidelines1,4Cost savings from Lenalidomide Sandoz can expand treatment options for patients with haemato-oncology conditions1,2Sandoz is comm…
Ad hoc announcement pursuant to Art. 53 LRQ4 sales grew +6% (cc1, +4% USD) and core operating income grew +12% (cc, +9% USD)IM sales grew +7% (cc, +5% USD) and core operating income +15% (cc, +12% USD)Sandoz sales grew +2% (cc, 0% USD) and core operati…
Ad hoc announcement pursuant to Art. 53 LRQ4 sales grew +6% (cc1, +4% USD) and core operating income grew +12% (cc, +9% USD)IM sales grew +7% (cc, +5% USD) and core operating income +15% (cc, +12% USD)Sandoz sales grew +2% (cc, 0% USD) and core operati…
Submission is supported by comprehensive package of analytical, pre-clinical and clinical data, proposed biosimilar trastuzumab developed by EirGenix, Inc. Breast cancer is one of most common types of cancer in women, accounting for over 355,000 new ca…